Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) EBITDA Margin (2024 - 2025)

Beta Bionics' EBITDA Margin history spans 2 years, with the latest figure at 41.77% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 4679.0% year-over-year to 41.77%; the TTM value through Dec 2025 reached 72.68%, up 1151.0%, while the annual FY2025 figure was 72.68%, 1151.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 41.77% at Beta Bionics, up from 51.39% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 41.77% in Q4 2025 and bottomed at 161.47% in Q1 2025.